Please assess the completion status of the following clinical trial:

Trial Title: Comparison of TAP, Anterior QL, or ESP Block for Elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesiologists (ASA) Physical Status 1-3~2. Age greater than or equal to 18 years~3. Scheduled for elective cesarean section~4. English speaking~Exclusion Criteria:~1. ASA Physical Status 4-5~2. Diagnosis of chronic pain~3. Chronic opioid use (opioid use in the past 3 months)~4. Preoperative use of SSRIs (Celexa, Lexapro, Prozac, Paxil), SNRIs (Cymbalta, Effexor), gabapentin, or pregabalin (Lyrica)~5. Inability to cooperate with or understand protocol~6. Inability to communicate pain scores or need for analgesia~7. Infection at the site of block placement~8. Intolerance or allergy to local anesthetics~9. Neurologic deficit or disorder~10. Blood thinning disorder or taking anticoagulant medication~11. BMI \> 50 kg/m2~12. Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years~13. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance~14. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TAP block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
- QL block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
- ESP block (Type: ACTIVE_COMPARATOR): Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.

Based on this trial design, predict the completion outcome and termination type (if applicable).